Overview

* InspireMD ( NSPR ) Q3 revenue grows 39% yr/yr, beating analyst expectations

* Net income for Q3 beats analyst estimates despite larger net loss

* Company attributes revenue growth to U.S. launch and international market penetration

Outlook

* InspireMD ( NSPR ) highlights strong demand for its CGuard Prime globally

* Company emphasizes strategic focus on U.S. commercial expansion

* InspireMD ( NSPR ) strengthens financial position with $58 mln in gross proceeds

Result Drivers

* U.S. LAUNCH - Successful U.S. commercial launch of CGuard Prime carotid stent system contributed significantly to revenue growth

* INTERNATIONAL PENETRATION - Increased penetration in international markets boosted revenue

* OPERATING EXPENSES - Rise in operating expenses due to U.S. personnel expansion and establishment of U.S. headquarters

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.52 $1.76

Revenue mln mln (2

Analysts

)

Q3 Net Beat -$12.71 -$14.60

Income mln mln (2

Analysts

)

Q3 Beat -$13.05 -$14.60

Income mln mln (2

From Analysts

Operatio )

ns

Q3 Basic -$0.17

EPS

Q3 Gross $864,000

Profit

Q3 $13.91

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for InspireMD Inc ( NSPR ) is $4.50, about 49.1% above its November 3 closing price of $2.29

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)